Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
President Trump announces multiple judicial nominees, accuses court...
Top House committees accuse Dem fundraising giant of...
Trump to rename Persian Gulf the Arabian Gulf...
‘New sheriff in town’: State finance leader rallies...
Trump announces MAHA advocate Casey Means will be...
Trump offers to help India, Pakistan amid growing...
Lone Republican becomes only lawmaker to vote against...
Trump halts military strikes on Houthis but expert...
Retired judges criticize Trump admin over arrest of...
REAL ID deadline comes and goes – airports...
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Investing

5 Biggest Pharmaceutical ETFs in 2025

by admin May 7, 2025
May 7, 2025
5 Biggest Pharmaceutical ETFs in 2025

The global pharmaceutical market reached a total value of US$1.38 trillion in 2024, according to Research and Markets, up significantly from the US$888 billion seen just over a decade earlier in 2010.

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the pharmaceutical industry instead of focusing solely on individual pharmaceutical stocks.

The main advantage of a pharmaceutical ETF is the fact that it can provide exposure to an overarching sector, but still trades like a stock. Pharma ETFs also offer less market volatility and lower fees and expenses.

Big pharma ETFs

Many of these funds have diverse holdings across some of the most important sectors in the pharmaceutical industry, including pain therapeutics, oncology, vaccines and biotechnology. Data was gathered on May 6, 2025.

1. VanEck Pharmaceutical ETF (NASDAQ:PPH)

Total assets under management: US$653.61 million

Established in late 2011, the VanEck Pharmaceutical ETF tracks the MVIS US Listed Pharmaceutical 25 Index. It has the capacity to provide big returns, even though there are some risks attached to the ETF. An analyst report indicates that investors looking for ‘tactical exposure’ to the pharma sector might consider this ETF as an investment option.

The ETF has 25 holdings, with the top five being Eli Lilly (NYSE:LLY) at a weight of 12.17 percent, AbbVie (NYSE:ABBV) at 6.48 percent, Johnson & Johnson (NYSE:JNJ) at 6.45 percent, Novartis (NYSE:NVS) at 5.43 percent and Cencora (NYSE:COR) at 5.34 percent.

2. iShares US Pharmaceuticals ETF (ARCA:IHE)

Total assets under management: US$571.51 million

Created on May 5, 2006, this iShares ETF tracks some of the top US pharma companies. In total, the iShares US Pharmaceuticals ETF has 41 holdings, with the vast majority being large-cap stocks.

Of its holdings, Eli Lilly and Johnson & Johnson are by far the largest portions in its portfolio, coming in at weightings of 24.55 percent and 23.38 percent, respectively. The next highest are Royalty Pharma (NASDAQ:RPRX) at 4.93 percent, Zoetis (NYSE:ZTS) at 4.80 percent and Viatris (NASDAQ:VTRS) at 4.57 percent.

3. Invesco Pharmaceuticals ETF (ARCA:PJP)

Total assets under management: US$240.1 million

The Invesco Pharmaceuticals ETF is primarily focused on providing exposure to US-based pharma companies. An analyst report states that this ETF chooses individual securities based on certain investment criteria, namely stock valuation and risk factors. Invesco changed the fund’s name from the Invesco Dynamic Pharmaceuticals ETF in August 2023.

This ETF was started on June 23, 2005, and currently tracks 31 companies. Its top holdings are Abbott Laboratories (NYSE:ABT) with a weight of 5.2 percent, AbbVie at 5.17 percent, Johnson & Johnson at 5 percent, Gilead Sciences (NASDAQ:GILD) at 4.94 percent and Eli Lilly at 4.86 percent.

4. SPDR S&P Pharmaceuticals ETF (ARCA:XPH)

Total assets under management: US$139.14 million

The SPDR S&P Pharmaceuticals ETF came into the market on June 19, 2006, and represents the pharmaceutical sub-industry sector of the S&P Total Markets Index. An analyst report for the ETF suggests that due to its narrow focus — which includes pharma giants that post ‘big returns’ during times of consolidation — it should not be considered for a long-term portfolio.

This pharma ETF tracks 43 holdings, with relatively close weighting among its holdings. XPH’s top five holdings are Corcept Therapeutics (NASDAQ:CORT) with a weight of 5.26 percent, Eli Lilly at 3.99 percent, Royalty Pharma (NASDAQ:RPRX) at 3.98 percent, Zoetis at 3.87 percent and Johnson & Johnson at 3.81 percent.

5. KraneShares MSCI All China Health Care Index ETF (ARCA:KURE)

Total assets under management: US$82.86 million

The KraneShares MSCI All China Health Care Index ETF was launched in February 2018 and tracks an index of large- and mid-cap Chinese stocks in the healthcare sector, all weighted by market capitalization. According to an analyst report, the fund provides investors with ‘exposure to a relatively small slice of the Chinese economy.’

The ETF tracks 46 holdings, and its top five are Jiangsu Hengrui Medicine (SHA:600276) at 8.33 percent, BeiGene (OTC Pink:BEIGF,HKEX:6160) at 7.88 percent, Shenzhen Mindray Bio-Medical Electronics (SZSE:300760) at 6.79 percent, Wuxi Biologics (OTC Pink:WXIBF,HKEX:2269) at 6.67 percent and Innovent Biologics (OTC Pink:IVBXF,HKEX:1801) at 5.51 percent .

Securities Disclosure: I, Melissa Pistilli, hold no investment interest in any of the companies mentioned in this article.

Keep reading…Show less

This post appeared first on investingnews.com

previous post
Quimbaya Gold and Denarius Metals Partner to Formalize Artisanal Mining at Tahami Project, Strengthening Long-Term Exploration Strategy
next post
Update – Blackstone Merger to Acquire Copper Gold Project

You may also like

New Generation Atomic Layer Deposition Machine Procured

November 11, 2024

Coniagas Battery Metals Completes Private Placement

October 1, 2024

Top 7 Global Lithium Stocks in 2025

April 4, 2025

Allup Strengthens its Board with Mine and Finance...

August 16, 2024

US Operations Update

November 28, 2024

Jindalee Lithium Limited (ASX: JLL) – Reinstatement to...

November 19, 2024

Electra Secures Federal Support for North America’s Only...

March 26, 2025

175m @ 2.5% Copper from 7.6m, Hole Ends...

May 6, 2025

4 Biggest Cybersecurity ETFs in 2025

January 14, 2025

Denison Mines Moves Closer to Federal Approval for...

March 1, 2025

Recent Posts

  • President Trump announces multiple judicial nominees, accuses court system of blocking him from doing his job
  • Top House committees accuse Dem fundraising giant of facilitating ‘bad actors’ in bombshell DOJ letter
  • Trump to rename Persian Gulf the Arabian Gulf ahead of US-Iran nuclear talks, Middle East trip: report
  • ‘New sheriff in town’: State finance leader rallies around key Trump victory saving ‘taxpayer dollars’
  • Trump announces MAHA advocate Casey Means will be new surgeon general nominee

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (710)
    • Investing (2,051)
    • Politics (2,543)
    • Stock (4)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 Sightful Invest. All Rights Reserved.